Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review (Q21284663)

1 reference

25 April 2019

1 reference

2 October 2019

Giovambattista De Sarro

6

object named as

Giovambattista De Sarro

Giovambattista

De Sarro

1 reference

19 August 2022

Domenico Pirritano

1

Domenico

Pirritano

1 reference

19 August 2022

Massimiliano Plastino

2

Massimiliano

Plastino

1 reference

19 August 2022

Domenico Bosco

3

Domenico

Bosco

1 reference

19 August 2022

Luca Gallelli

4

Luca

Gallelli

1 reference

19 August 2022

Antonio Siniscalchi

5

Antonio

Siniscalchi

1 reference

BioMed Research International

19 August 2022

language of work or name

English

0 references

publication date

8 July 2014

6 references

11 March 2019

13 March 2019

25 April 2019

2 October 2019

8 October 2022

26 October 2022

7 references

11 March 2019

13 March 2019

25 April 2019

2 October 2019

8 October 2022

26 October 2022

2014

0 references

page(s)

728038

0 references

copyright license

Creative Commons Attribution 3.0 Unported

6 references

11 March 2019

13 March 2019

25 April 2019

2 October 2019

8 October 2022

on focus list of Wikimedia project

26 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

DSM-5 gambling disorder: prevalence and characteristics in a substance use disorder sample

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Brain γ-aminobutyric acid: a neglected role in impulsivity

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

A review on antiepileptic drugs-dependent fatigue: pathophysiological mechanisms and incidence.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological gambling in Parkinson's disease. A comprehensive review

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Imaging impulse control disorders in Parkinson's disease and their relationship to addiction

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological gambling: a general overview

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

What's the role of topiramate in the management of patients with hyperkinetic movement disorders?

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Antiepileptic drugs for central post-stroke pain management.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Clinical aspects of impulsive compulsive behaviours in Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Reward processing abnormalities in Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological Gambling: Biological and Clinical Considerations

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Current use of clozapine in Parkinson disease and related disorders

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Dopamine and impulse control disorders in Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Impulse-control disorders in Parkinson's disease.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Gambling, health and age: data from the National Epidemiologic Survey on Alcohol and Related Conditions

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Long-term follow-up of impulse control disorders in Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

There and back again: a tale of norepinephrine and drug addiction

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Association of dopamine agonist use with impulse control disorders in Parkinson disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological gambling caused by drugs used to treat Parkinson disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Decision-making impairments in patients with Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Therapeutic strategies for neurodegenerative disorders: emerging clues from Parkinson's disease.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Impulse control disorders: clinical characteristics and pharmacological management

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling

12 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

12 September 2017

https://api.crossref.org/works/10.1155%2F2014%2F728038

Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological gambling. A psychobiological study

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Management of impulse control disorders in Parkinson's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

An open-label study of citalopram in the treatment of pathological gambling

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Aripiprazole-induced pathological gambling: a report of 3 cases

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Sertraline treatment of pathological gambling: a pilot study

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Cognitive impairments in advanced PD without dementia.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Psychiatry. Behavioral addictions debut in proposed DSM-V.

30 May 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Prevalence of pathological gambling in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Pramipexole in comparison to l-dopa: a neuropsychological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Pathological gambling associated with dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Iowa gambling task impairment in Parkinson's disease can be normalised by reduction of dopaminergic medication after subthalamic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Impulse control disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Pathological gambling is linked to reduced activation of the mesolimbic reward system

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Gambling urges in pathological gambling: a functional magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Functional abnormalities underlying pathological gambling in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Dopaminergic and GABA-ergic markers of impulsivity in rats: evidence for anatomical localisation in ventral striatum and prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Pathologic gambling in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Compulsive drug use linked to sensitized ventral striatal dopamine transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Dopamine agonist withdrawal syndrome in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

A pilot placebo-controlled study of fluvoxamine for pathological gambling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Disabling repetitive behaviors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Clozapine for medication‐related pathological gambling in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Possible zoophilia associated with dopaminergic therapy in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Aripiprazole in schizophrenia with cocaine dependence: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Topiramate in managing impulse control disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Zonisamide in managing impulse control disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

An open naltrexone treatment study in pathological gambling disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Motivational enhancement and self-help treatments for problem gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

Prevalence of repetitive and reward-seeking behaviors in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Opioid antagonists in the treatment of impulse-control disorders.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

Cognitive and behavioral treatment of pathological gambling: a controlled study

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4119624

A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling

29 November 2018

1 reference

12 December 2020

Clinical features associated with impulse control disorders in Parkinson disease

1 reference

12 December 2020

Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease

1 reference

12 December 2020

Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study

1 reference

12 December 2020

Quetiapine in a case with Parkinson disease and pathological gambling

1 reference

12 December 2020

Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis

1 reference

12 December 2020

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

1 reference

12 December 2020

Updating and refining prevalence estimates of disordered gambling behaviour in the United States and Canada

1 reference

12 December 2020

Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists

1 reference

12 December 2020

Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors

1 reference

12 December 2020

Sertraline Treatment of Pathological Gambling

1 reference

https://api.crossref.org/works/10.1155%2F2014%2F728038

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1155/2014/728038

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4825766

OpenCitations bibliographic resource ID

4825766

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4825766

PMC publication ID

4119624

0 references